[99mTc]Tc-DB8

Phase 2

TTomsk National Research Medical Center of the Russian Academy of Sciences

[99mTc]Tc-DB8 is one of 3 therapeutic programs targeting Primary Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary Breast CancerEnrolling by invitation

Primary Breast CancerPhase 2

Enrolling by invitation

Competition

Competitive Landscape

4 competitors in Primary Breast Cancer

#DrugCompanyPhaseTrials

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 2

Trastuzumab Emtansine

SSeoul National University Bundang Hospital

Phase 3

1 3

[99mTc]Tc-DB8

TTomsk National Research Medical Center of the Russian Academy of Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Breast Cancer1 trial

SPECT/CT Imaging of Gastrin-releasing Peptide Receptor Expression in Breast Cancer With Different Estrogen Receptor Expression Using Technetium-99m-labelled DB8 [99mTc]Tc-DB8

Enrolling by invitation·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 2·NCT07275463·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [99mTc]Tc-DB8. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [99mTc]Tc-DB8. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tomsk National Research Medical Center of the Russian Academy of Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTomsk National Research Medical Center of the Russian Academy of Sciences

[99mTc]Tc-DB8

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Primary Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News